Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

<p>Abstract</p> <p>Background</p> <p>The pathological complete response (pCR) after neoadjuvant chemotherapy is a surrogate marker for a favorable prognosis in breast cancer patients. Factors capable of predicting a pCR, such as the proliferation marker Ki67, may theref...

Full description

Bibliographic Details
Main Authors: Fasching Peter A, Heusinger Katharina, Haeberle Lothar, Niklos Melitta, Hein Alexander, Bayer Christian M, Rauh Claudia, Schulz-Wendtland Ruediger, Bani Mayada R, Schrauder Michael, Kahmann Laura, Lux Michael P, Strehl Johanna D, Hartmann Arndt, Dimmler Arno, Beckmann Matthias W, Wachter David L
Format: Article
Language:English
Published: BMC 2011-11-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/11/486

Internet

http://www.biomedcentral.com/1471-2407/11/486

Similar Items